![[Adobe Stock]](https://sp-ao.shortpixel.ai/client/to_webp,q_glossy,ret_img,w_750,h_375/https://www.psypost.org/wp-content/uploads/2023/12/cannabidiol-cbd-750x375.jpg)
A compound found in cannabis may help reduce alcohol addiction and withdrawal symptoms, according to new research in animals that suggests the substance could protect the brain from damage caused by heavy drinking. This study was published in the journal Neuropsychopharmacology.
Alcohol addiction remains a serious global health issue. People with alcohol use disorder often struggle with uncontrollable drinking and experience severe withdrawal symptoms when they try to stop. While several medications exist to help treat alcohol addiction, many provide only limited benefits or cause unwanted side effects.
A potential alternative is cannabidiol (CBD), a naturally occurring compound in the cannabis plant. Unlike THC, it does not produce the “high” associated with marijuana. Recently, researchers have studied CBD for a variety of medical uses, such as reducing anxiety and treating epilepsy.
Previous animal studies hinted that CBD might also reduce alcohol consumption and alcohol-seeking behavior. However, many of those experiments involved animals that were not fully dependent on alcohol, and the new research aimed to explore whether CBD could help in cases that more closely resemble severe, established alcohol addiction.
Conducted by a team at the University of California San Diego and led by senior author Giordano de Guglielmo, the researchers conducted a series of experiments using 166 rats (87 males and 79 females) that were exposed to alcohol over long periods. In one model, rats were repeatedly exposed to alcohol vapor to induce physical dependence and mimic the severe neuroadaptive changes seen in human alcoholics.
In another model, the animals voluntarily self-administered alcohol vapor, allowing researchers to observe patterns similar to the human transition from casual drinking to compulsive habits. The researchers then injected some of the animals with regular doses of CBD and compared their behavior and brain changes with rats that did not receive the compound.
The results revealed that rats treated with CBD drank significantly less alcohol during acute withdrawal periods and showed fewer physical withdrawal symptoms. They also displayed reduced anxiety-like behaviors and decreased sensitivity to physical pain, which are common during alcohol withdrawal and often drive patients to relapse.
To ensure CBD was specifically targeting alcohol addiction and not simply reducing the animals’ overall desire for any reward, the researchers also offered the rats sweet saccharin water. CBD had no effect on their consumption of the sugar water, proving its therapeutic effects were specific to alcohol-motivated behavior.
CBD also fundamentally changed how the animals’ brains responded to alcohol. The compound restored normal electrical activity in a brain region called the basolateral amygdala, which is heavily involved in stress, emotional regulation, and addiction-related behavior. Severe chronic alcohol use had previously depressed and disrupted this region’s electrical excitability.
In addition, CBD acted as a neuroprotectant. While chronic alcohol exposure usually causes brain cell death and inflammation, CBD prevented this damage specifically in the nucleus accumbens shell and the dorsomedial striatum. These specific brain areas control voluntary, goal-directed behavior, suggesting CBD may help prevent the brain from shifting into a state of compulsive, uncontrollable habit.
Another important finding was that CBD successfully blocked relapse-like behavior triggered by severe stress, a major cause of relapse in people recovering from addiction.
Importantly, CBD did not appear to increase the sedative effects of alcohol or interfere with normal movement, indicating that the compound’s benefits were not simply due to making animals too impaired to drink.
De Guglielmo and colleagues concluded, “Chronic CBD administration mitigates key behavioral and neurobiological features of alcohol dependence by reducing withdrawal symptoms, lowering relapse risk, restoring basolateral amygdala neuronal excitability, and preventing neurodegeneration.”
Despite the promising results coming from animal experiments, the researchers are optimistic about human applications. The study noted that the blood-plasma levels of CBD achieved in these rats closely match the safe therapeutic levels already seen in humans taking FDA-approved oral CBD for conditions like epilepsy. This makes the findings highly translatable, though further clinical trials will be necessary to determine optimal dosing to treat alcohol addiction in humans.
The study, “Cannabidiol mitigates alcohol dependence and withdrawal with neuroprotective effects in the basolateral amygdala and striatum,” was authored by Selen Dirik, Michelle R. Doyle, Courtney P. Wood, Paola Campo, Angelica R. Martinez, McKenzie Fannon, Maria G. Balaguer, Spencer Seely, Bryan A. Montoya, Gregory M. R. Cook, Gabrielle M. Palermo, Junjie Lin, Madelyn D. Sist, Parsa K. Naghshineh, Zihang Lan, Sara R. M. U. Rahman, Raymond Suhandynata, Paul Schweitzer, Marsida Kallupi, and Giordano de Guglielmo.
